# Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

> **NCT03739138** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** MK-4621
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03739138
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-18
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739138, "Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03739138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*